beating cancer sooner: rising to the challenge
TRANSCRIPT
BEATING CANCER SOONER: RISING TO THE CHALLENGE
Harpal KumarChief Executive Officer
Cancer Research UK
CANCER RESEARCH UK
OUR STRATEGY
OUR RESEARCH STRATEGY
CANCER RESEARCH UK IN WALES
CANCER INCIDENCE IN WALES IS HIGH IN UK
Source: UK Official/national statistics
CANCER SURVIVAL AND MORTALITY IS IMPROVING IN WALES
MORTALITY
60.7%65.9%
69.4%72.7%
43.9%49.7%
53.8%57.1%
1 2 3 4
One year survival
1995-1999 2000-2004 2005-2009 2010-2014
Five year survival
Year of diagnosis
SURVIVAL
EASR per 100,000 population
0 50 100 150 200 250 300 350 400
Powys THB
Hywel Dda UHB
Wales
Abertawe Bro Morgannwg UHB
Cardiff & Vale UHB
Betsi Cadwaladr UHB
Aneurin Bevan UHB
Cwm Taf UHB
EARLY DIAGNOSIS IS KEY FOR IMPROVING SURVIVAL
EARLY DIAGNOSIS IS KEY FOR IMPROVING SURVIVAL
5 related modules
Module 1: Epidemiological benchmarking study
Module 2: Public awareness, attitudes and beliefs
Module 3: The role of primary care and healthcare systems
Module 4: Variation in patient, diagnostic and treatment time intervals and routes to diagnosis
Module 5: Data comparability and early deaths (with an initial focus on co-morbidity for lung cancer)
Phase 219 jurisdictions, 5 countries+ Ireland+ New Zealand+ Canadian provinces+ Australian states
- Sweden- Denmark
8 cancer sites+ Oesophagus+ Stomach + Liver+ Pancreatic
- Breast
THE INTERNATIONAL CANCER BENCHMARKING PARTNERSHIP
0% 10% 20% 30% 40% 50% 60% 70%
Australian registriesSwedish Regions
Canadian RegistriesNorway
DenmarkNorthern Ireland
UK (excluding Scotland)England
Wales
0% 5% 10% 15% 20%
Swedish RegionsCanadian RegistriesAustralian registries
NorwayDenmark
Northern IrelandUK (excluding Scotland)
EnglandWales
76% 78% 80% 82% 84% 86% 88% 90%
Swedish Regions
Australian registries
Norway
Canadian Registries
Denmark
Northern Ireland
England
UK (excluding Scotland)
Wales
32% 34% 36% 38% 40% 42% 44%
Canadian Registries
Norway
Australian registries
Denmark
England
UK (excluding Scotland)
Northern Ireland
Wales
ICBP MODULE 1: SURVIVAL BENCHMARK (2011)
THERE ARE DIFFERENCES IN TIME INTERVALS ALONG THE PATHWAY
Intervals for colorectal cancer (median, days) [Unpublished]
0 20 40 60 80 100 120 140 160
Wales
England
Scotland
N Ireland
Denmark
Manitoba
Norway
Sweden
Ontario
Victoria
Patient Diagnostic Treatment
MANY OPPORTUNITIES FOR IMPROVEMENTS ALONG THE CANCER PATHWAY
UPTAKE OF BOWEL CANCER SCREENING IS POOR
44.0%
46.0%
48.0%
50.0%
52.0%
54.0%
56.0%
58.0%
Abertawe BroMorgannwgUniversity
Aneurin BevanUniversity
BetsiCadwaladrUniversity
Cardiff & ValeUniversity
Cwm TafUniversity
Hywel DdaUniversity
PowysTeaching
WALES TOTAL
2014 2015 2016
FIT IMPLEMENTATION IS EXPECTED TO IMPROVE UPTAKE
• Expected to be introduced early 2019 – after Scotland and England
• A simpler test = increased uptake?
• Impact on endoscopy services
• A missed opportunity if the sensitivity threshold is
set too high
FOCUS ON DIAGNOSTIC CAPACITY
• Diagnostic spend
• Diagnostic workforce
• Infrastructure
• Raising the profile of diagnostic services
• Modelling future demand and requesting additional resource on the basis of need.
MULTIDISCIPLINARY DIAGNOSTIC CENTRES TO IMPROVE VAGUE SYMPTOMS PATHWAYS
Neath Port Talbot
Royal Glamorgan
NATIONAL CANCER DIAGNOSIS AUDIT (NCDA)
• The NCDA seeks to gather data about:• Interval length and number of consultations in primary care
• Use of investigations prior to referral
• Referral pathways for patients with cancer
• Benefits for practices and health boards
• Plans to re-run the audit across Wales
THE IMPORTANCE OF DATA
Data
Information
IntelligenceInfluence
Actions
OUR RESEARCH STRATEGY
SUPPORTING THE RESEARCH ENVIRONMENT
OUR NEW GRANDCHALLENGES
THE IMPORTANCE OF PREVENTION
THE CHALLENGE AND OPPORTUNITIES FOR WALES
• Cancer must remain a priority in Wales• Services
• Research
• Opportunities – size, structures
• Can Wales’ survival catch up to international comparators?
BEATING CANCER SOONER: RISING TO THE CHALLENGE
THANK YOU